Table 1 Baseline demographic and characteristics of patients with IBD enrolled in this study
Variable | Crohn’s disease n = 16 | Ulcerative colitis n = 67 |
|---|---|---|
Age, median [years](± IQR) | 34.5 (± 20.25) | 35 (± 15.25) |
BMI, mean [kg/m²] (± SD) | 33.54 (± 6.2) | 24.17 (± 5.9) |
Male, n (%) | 10 (62.5%) | 39 (58.2%) |
Smoking, n (%) | 6 (37.5%) | 17 (25.3%) |
Alcohol use, n (%) | 1 (6.2%) | 7 (10.4%) |
Drug abuse, n (%) | 1 (6.2%) | 4 (6%) |
Familial history of IBD, n (%) | 2 (12.5%) | 5 (7.5%) |
Complications, n (%) | ||
Diarrhea | 12 (75%) | 51(76.1%) |
Bloody diarrhea | 7 (43.7%) | 38 (56.7%) |
Constipation | 1 (6.2%) | 3 (4.5%) |
weakness | 2 (12.5%) | 12 (17.9%) |
Weight loss | 3 (18.7%) | 19 (28.3%) |
Hematochezia | 0 (0) | 10 (14.9%) |
Fever | 0 (0) | 2 (3%) |
Nausea and Vomiting | 0 (0) | 12 (17.9%) |
Laboratory results, median (± IQR) | ||
WBC, ×109/L | 9.1 (± 0.5) | 5.9 * 103 (± 5) |
Hemoglobin, g/dL | 12.21 (± 4.14) | 10.7 (± 5) |
Platelets, ×109/L | 244.5 (± 18.75) | 261 (± 81) |
MCV, femtoliter | 83.3 (± 8.45) | 92.8 (± 14.4) |
ESR, mm/hr | 24 (± 21.75) | 51 (± 16.75) |
CRP, mg/dL | 75 (± 44.9) | 62.5 (± 36.75) |
Total bilirubin, mg/dL | 0.65 (± 0.37) | 0.7 (± 1.15) |
Direct bilirubin, mg/dL | 0.2 (± 0.7) | 0.2 (± 0.35) |
AST, U/L | 23 (± 9.75) | 26 (± 56) |
ALT, U/L | 18 (± 6.5) | 23 (± 43) |
ALP, U/L | 165.5 (± 37) | 173 (± 100) |
BUN, mg/dL | 15 (± 9) | 15 (± 7) |
Medications, n (%) | ||
β-lactams | 5 (31.2%) | 21 (31.3%) |
Fluoroquinolones | 7 (43.7%) | 25 (37.3%) |
Metronidazole | 7 (43.7%) | 23 (34.3%) |
NSAIDs | 7 (43.7%) | 37 (55.2%) |
SID | 1 (6.2%) | 14 (20.8%) |
PPI | 4 (25%) | 12 (17.9%) |
Anti-TNF biologics | 6 (37.5%) | 29 (43.3%) |
Disease activity index, median (range) | ||
Mayo Score | - | 9 (3–12) |
CDAI | 129 (56–348) | - |